Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 3/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 10/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 10/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 10/20 | 0.47 |
| ▸ | OPRL1 | P41146 | 10/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2180514 | 1.00 | DPP4 (0.48) | DPP4OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL2180510 | 1.00 | DPP4 (0.48) | DPP4OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL2179872 | 0.90 | OPRM1 (0.50) | DPP4OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL2179875 | 0.90 | OPRM1 (0.50) | DPP4OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL2179868 | 0.90 | OPRM1 (0.50) | DPP4OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL2178205 | 0.84 | SLC6A4 (0.53) | DPP4 | |
| SCHEMBL2178201 | 0.84 | SLC6A4 (0.53) | DPP4 | |
| SCHEMBL2178207 | 0.84 | SLC6A4 (0.53) | DPP4 | |
| SCHEMBL2179651 | 0.81 | CYP2D6 (0.51) | DPP4OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL2179644 | 0.81 | CYP2D6 (0.51) | DPP4OPRM1OPRD1OPRK1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2351738-A1 | PROCESS FOR PRODUCING 1-SUBSTITUTED TRANS-4-(SUBSTITUTED AMINO)PIPERIDIN-3-OL | Sumitomo Chemical Company, Limited (JP) | 2011-08-03 | — | — | EP | disclosed |
| US-20110172431-A1 | PROCESS FOR PRODUCING 1-SUBSTITUTED TRANS-4-(SUBSTITUTED AMINO) PIPERIDIN-3-OL | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-07-14 | — | — | US | disclosed |
| US-20110166357-A1 | METHOD FOR PRODUCING N-SUBSTITUTED-TRANS-4-AZIDOPIPERIDINE-3-OL | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166357-A1 | METHOD FOR PRODUCING N-SUBSTITUTED-TRANS-4-AZIDOPIPERIDINE-3-OL | RPS27L, OSGEP, RPLP1 | DPP4 4436/4885OPRM1 29/4885OPRD1 40/4885 |
| US-20110172431-A1 | PROCESS FOR PRODUCING 1-SUBSTITUTED TRANS-4-(SUBSTITUTED AMINO) PIPERIDIN-3-OL | TEAD4, TEAD3, TEAD2 | DPP4 2071/4885OPRM1 134/4885OPRD1 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.